Syndax Pharma shares are trading higher after the company announced topline results of its trial of Axatilimab in chronic graft-versus-host disease.
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharma announced positive topline results of its trial of Axatilimab in chronic graft-versus-host disease, leading to a rise in its share prices.
July 24, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharma's stock is trading higher after the company announced positive results from its Axatilimab trial.
The positive results from the Axatilimab trial indicate a potential new revenue stream for Syndax Pharma, which is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100